BeiGene ups of­fer­ing to a whop­ping $750M; Cel­gene back­ing $475M raise for Agios; Avastin copy­cat OK'd for Eu­rope

→ In a demon­stra­tion of its pop­u­lar­i­ty, BeiGene $BGNE has priced its pub­lic of­fer­ing at $750 mil­lion — quite a bit more than the $650 mil­lion it had pro­posed ear­li­er in the week. A promis­ing can­di­date for in­vestors look­ing to get in on emerg­ing Chi­nese com­pa­nies, the biotech is hard at work with sev­er­al check­point drugs, one of which it’s de­vel­op­ing with part­ner Cel­gene $CELG. It plans to use the mon­ey for gen­er­al pur­pos­es, in­clud­ing re­search and de­vel­op­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER